AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
Couch or crouch? Examining the prostate: a randomized study comparing the knee-elbow and the left-lateral position
Authors: Schellhammer, PF
Citation: Pf. Schellhammer, Couch or crouch? Examining the prostate: a randomized study comparing the knee-elbow and the left-lateral position, BJU INT, 88(6), 2001, pp. 645-645
Glansectomy: an alternative surgical treatment for Buschke-Lowenstein tumours of the penis
Authors: Davis, JW Schellhammer, PF
Citation: Jw. Davis et Pf. Schellhammer, Glansectomy: an alternative surgical treatment for Buschke-Lowenstein tumours of the penis, BJU INT, 88(6), 2001, pp. 647-647
First Annual Midwinter Meeting - Society of Urologic Oncology - Introduction to the special issue
Authors: Schellhammer, PF
Citation: Pf. Schellhammer, First Annual Midwinter Meeting - Society of Urologic Oncology - Introduction to the special issue, UROL ONCOL, 6(5), 2001, pp. 175-175
Luteinizing hormone-releasing hormone monotherapy: A viable option for treatment of prostate cancer?
Authors: Schellhammer, PF
Citation: Pf. Schellhammer, Luteinizing hormone-releasing hormone monotherapy: A viable option for treatment of prostate cancer?, UROLOGY, 58(2A), 2001, pp. 10-15
Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systematic review
Authors: Schmitt, B Wilt, TJ Schellhammer, PF DeMasi, V Sartor, O Crawford, ED Bennett, CL
Citation: B. Schmitt et al., Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: A systematic review, UROLOGY, 57(4), 2001, pp. 727-732
Quality of life after treatment for localized prostate cancer: Differencesbased on treatment modality
Authors: Davis, JW Kuban, DA Lynch, DF Schellhammer, PF
Citation: Jw. Davis et al., Quality of life after treatment for localized prostate cancer: Differencesbased on treatment modality, J UROL, 166(3), 2001, pp. 947-952
Prostatorectal fistula 14 years following brachytherapy for prostate cancer
Authors: Davis, JW Schellhammer, PF
Citation: Jw. Davis et Pf. Schellhammer, Prostatorectal fistula 14 years following brachytherapy for prostate cancer, J UROL, 165(1), 2001, pp. 189-189
Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease
Authors: Xiao, Z Adam, BL Cazares, LH Clements, MA Davis, JW Schellhammer, PF Dalmasso, EA Wright, GL
Citation: Z. Xiao et al., Quantitation of serum prostate-specific membrane antigen by a novel protein biochip immunoassay discriminates benign from malignant prostate disease, CANCER RES, 61(16), 2001, pp. 6029-6033
Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy
Authors: Incognito, LS Cazares, LH Schellhammer, PF Kuban, DA Van Dyk, EO Moriarty, RP Wright, GL Somers, KD
Citation: Ls. Incognito et al., Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapy, INT J ONCOL, 17(4), 2000, pp. 761-769
The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer - A Southwest Oncology Group Study
Authors: White, RWD Deitch, AD Daneshmand, S Blumenstein, B Lowe, BA Sagalowsky, AI Smith, JA Schellhammer, PF Stanisic, TH Grossman, HB Messing, E Crissman, JD Crawford, ED
Citation: Rwd. White et al., The prognostic significance of S-phase analysis in stage Ta/T1 bladder cancer - A Southwest Oncology Group Study, EUR UROL, 37(5), 2000, pp. 595-600
Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia
Authors: Wright, GL Beckett, ML Newhall, KR Adam, BL Cazares, LH Cartwright, SL Xiao, Z Gong, L Schellhammer, PF
Citation: Gl. Wright et al., Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia, PROSTATE, 42(3), 2000, pp. 230-238
Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: Cost implications of a clinical trial for valrubicin
Authors: Marchetti, A Wang, LP Magar, R Grossman, HB Lamm, DL Schellhammer, PF Erwin-Toth, P
Citation: A. Marchetti et al., Management of patients with Bacilli Calmette-Guerin-refractory carcinoma in situ of the urinary bladder: Cost implications of a clinical trial for valrubicin, CLIN THER, 22(4), 2000, pp. 422-438
Fifteen-year minimum follow-up of a prostate brachytherapy series: Comparing the past with the present
Authors: Schellhammer, PF Moriarty, R Bostwick, D Kuban, D
Citation: Pf. Schellhammer et al., Fifteen-year minimum follow-up of a prostate brachytherapy series: Comparing the past with the present, UROLOGY, 56(3), 2000, pp. 436-439
Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?
Authors: Sarosdy, MF Schellhammer, PF Johnson, R Carroll, K Kolvenbag, GJCM
Citation: Mf. Sarosdy et al., Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy?, UROLOGY, 55(3), 2000, pp. 391-395
Ultrasound-guided brachytherapy: Is it really better?
Authors: Schellhammer, PF
Citation: Pf. Schellhammer, Ultrasound-guided brachytherapy: Is it really better?, UROLOGY, 55(2), 2000, pp. 300-300
Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transition cell carcinoma
Authors: Kondylis, FI Demirci, S Ladaga, L Kolm, P Schellhammer, PF
Citation: Fi. Kondylis et al., Outcomes after intravesical bacillus Calmette-Guerin are not affected by substaging of high grade T1 transition cell carcinoma, J UROL, 163(4), 2000, pp. 1120-1123
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia
Authors: Roehrborn, CG McConnell, J Bonilla, J Rosenblatt, S Hudson, PB Malek, GH Schellhammer, PF Bruskewitz, R Matsumoto, AM Harrison, LH Fuselier, HA Walsh, P Roy, J Andriole, G Resnick, M Waldstreicher, J
Citation: Cg. Roehrborn et al., Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia, J UROL, 163(1), 2000, pp. 13-20
Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer
Authors: Ciavarra, RP Somers, KD Brown, RR Glass, WF Consolvo, PJD Wright, GL Schellhammer, PF
Citation: Rp. Ciavarra et al., Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer, CANCER RES, 60(8), 2000, pp. 2081-2084
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer
Authors: Sarosdy, MF Schellhammer, PF Soloway, MS Vogelzang, NJ Crawford, ED Presti, J Chodak, GW Mitchell, P Porter, L
Citation: Mf. Sarosdy et al., Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer, BJU INT, 83(7), 1999, pp. 801-806
Proteinchip((R)) surface enhanced laser desorption/ionization (SELDI) massspectrometry: a novel protein biochip technology for detection of prostatecancer biomarkers in complex protein mixtures
Authors: Wright, GL Cazares, LH Leung, SM Nasim, S Adam, BL Yip, TT Schellhammer, PF Gong, L Vlahou, A
Citation: Gl. Wright et al., Proteinchip((R)) surface enhanced laser desorption/ionization (SELDI) massspectrometry: a novel protein biochip technology for detection of prostatecancer biomarkers in complex protein mixtures, PROSTATE C, 2(5-6), 1999, pp. 264-276
Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer
Authors: Beckett, ML Cazares, LH Vlahou, A Schellhammer, PF Wright, GL
Citation: Ml. Beckett et al., Prostate-specific membrane antigen levels in sera from healthy men and patients with benign prostate hyperplasia or prostate cancer, CLIN CANC R, 5(12), 1999, pp. 4034-4040
Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with risingprostate-specific antigen levels after radical prostatectomy
Authors: Cox, JD Gallagher, MJ Hammond, EH Kaplan, RS Schellhammer, PF Crook, JM Leibel, SA Forman, JD Grimm, PD Zietman, AL Hudson, MA Schild, SA Beyer, DC Hussey, DH Thames, H Shipley, WU
Citation: Jd. Cox et al., Consensus statements on radiation therapy of prostate cancer: Guidelines for prostate re-biopsy after radiation and for radiation therapy with risingprostate-specific antigen levels after radical prostatectomy, J CL ONCOL, 17(4), 1999, pp. 1155-1163
Should we delay prostate radiotherapy?
Authors: Petersen, JP Schellhammer, PF
Citation: Jp. Petersen et Pf. Schellhammer, Should we delay prostate radiotherapy?, J CL ONCOL, 17(4), 1999, pp. 1326-1326
Prostatic carcinoma
Authors: Lawton, CA Grignon, D Newhouse, JH Schellhammer, PF Kuban, DA
Citation: Ca. Lawton et al., Prostatic carcinoma, RADIOGRAPHI, 19(1), 1999, pp. 185-203
Exploratory analysis on the effect of race on clinical outcome in patientswith advanced prostate cancer receiving bicalutamide or flutamide, each incombination with LHRH analogues
Authors: McLeod, DG Schellhammer, PF Vogelzang, NJ Soloway, MS Sharifi, R Block, NL Venner, PM Patterson, AL Sarosdy, MF Kelley, RP Kolvenbag, GJCM
Citation: Dg. Mcleod et al., Exploratory analysis on the effect of race on clinical outcome in patientswith advanced prostate cancer receiving bicalutamide or flutamide, each incombination with LHRH analogues, PROSTATE, 40(4), 1999, pp. 218-224
Risultati: 1-25 | 26-33